<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814463</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00004373</org_study_id>
    <secondary_id>DUMC-PRO00004373</secondary_id>
    <secondary_id>CDR0000630239</secondary_id>
    <nct_id>NCT00814463</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases</brief_title>
  <official_title>Phase II Single-arm Study of Post-operative Stereotactic Radiosurgery for Brain Metastases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and
      cause less damage to normal tissue. Giving stereotactic radiosurgery after surgery may kill
      any tumor cells that remain after surgery.

      PURPOSE: This phase II trial is studying how well stereotactic radiosurgery works in treating
      patients with brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To estimate the rate of recurrence at the surgical site in patients with brain
           metastases treated with adjuvant stereotactic radiosurgery (SRS) compared with
           historical data documenting recurrence at the surgical site after surgery and whole
           brain radiotherapy (WBRT).

      Secondary

        -  To estimate the rate of salvage WBRT, SRS, or surgery in patients treated with adjuvant
           SRS alone.

        -  To estimate the rate of new brain metastases outside of the adjuvant SRS site.

        -  To estimate patient quality of life after adjuvant SRS alone.

        -  To assess the effect of surgical intervention and SRS on the preservation of
           neurocognitive functioning in these patients.

        -  To determine the clinical significance (if any) of locally recurrent brain metastases at
           the time of their occurrence (mass effect, cognitive functioning, and other symptoms) in
           these patients.

        -  To estimate the rate of death due to neurologic causes, defined as death attributable to
           the progression of neurological disease.

        -  To estimate the overall survival of these patients.

      OUTLINE: Patients undergo stereotactic radiosurgery over 30-90 minutes.

      Quality of life and neurocognitive function are assessed periodically.

      After completion of study therapy, patients are followed every 3 months for 1 year and then
      every 6 months for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Early analysis indicated SRS not as beneficial post-op as pre-op
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence Rate at the Surgical Site as Measured by MRI</measure>
    <time_frame>12 months</time_frame>
    <description>The number of months for local recurrence via MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Salvage Whole-brain Radiotherapy, Stereotactic Radiosurgery (SRS), or Surgery</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of New Brain Metastases Outside of the Adjuvant SRS Site</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the FACT-Br Subscales</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preservation of Neurocognitive Function as Measured by the Mini-Mental State Exam</measure>
    <time_frame>Every 3 months for 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Significance (if Any) of Locally Recurrent Brain Metastasis at the Time of Their Occurrence (Mass Effect, Cognitive Functioning, and Other Symptoms)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Death Due to Neurologic Causes</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Post-operative SRS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MMSE</intervention_name>
    <description>Neurocognitive function via MMSE done every 3 months for length of study.</description>
    <arm_group_label>Post-operative SRS</arm_group_label>
    <other_name>Mini-Mental Status Exam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>QOL via FACT-Br</intervention_name>
    <description>Quality of Life via FACT-BR every 3 months for length of study.</description>
    <arm_group_label>Post-operative SRS</arm_group_label>
    <other_name>Quality of Life</other_name>
    <other_name>Functional Assessment of Cancer Therapy - Brain</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI done every 3 months for the length of the study.</description>
    <arm_group_label>Post-operative SRS</arm_group_label>
    <other_name>Magnetic Resonance Imagine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Post-operative SRS</intervention_name>
    <description>Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.</description>
    <arm_group_label>Post-operative SRS</arm_group_label>
    <other_name>SRS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 years of age.

          2. Gross total resection (as verified by the lack of any enhancement in the resection
             cavity on post-operative MRI) of single brain metastasis confirmed by histology.
             Patients with up to 4 metastases are eligible if the largest mass is amenable to
             surgical resection and all non-resected masses are amenable to SRS.

          3. Patient must be Radiation Therapy Oncology Group (RTOG) recursive partitioning
             analysis (RPA) Class 1 or 2.

          4. Life expectancy of at least 3 months.

        Exclusion Criteria:

          1. Radiographic or cytologic evidence of leptomeningeal disease.

          2. Patient with incomplete or partial resection.

          3. Primary lesion with radiosensitive histology (i.e., small cell carcinoma, germ-cell
             tumors, lymphoma, leukemia, and multiple myeloma).

          4. Patients with a resection cavity &gt; 4 cm in maximal extent in any plane on contrasted
             MRI scan.

          5. Lesion located in anatomic regions which are not amenable to SRS including the brain
             stem and optic apparatus.

          6. Pregnant or need to breast feed during the study period.

          7. Uncontrolled intercurrent illness including, but not limited to symptomatic congestive
             heart failure, unstable angina pectoris, or psychiatric illness.

          8. Brain surgery other than for resection of metastasis.

          9. Previous brain radiotherapy.

         10. Contraindication to SRS, WBRT, or MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H. Sampson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hamidreza Aliabadi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John P. Kirkpatrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James E. Herndon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2008</study_first_posted>
  <results_first_submitted>January 23, 2013</results_first_submitted>
  <results_first_submitted_qc>May 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2013</results_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the Duke Comprehensive Cancer Center from 6/12/2008 - 6/5/2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Post-operative SRS</title>
          <description>All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
QOL via FACT-Br : Quality of Life via FACT-BR every 3 months for length of study.
Post-operative SRS : Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
MMSE : Neurocognitive function via MMSE done every 3 months for length of study.
MRI : MRI done every 3 months for the length of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Post-operative SRS</title>
          <description>All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
QOL via FACT-Br : Quality of Life via FACT-BR every 3 months for length of study.
Post-operative SRS : Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
MMSE : Neurocognitive function via MMSE done every 3 months for length of study.
MRI : MRI done every 3 months for the length of the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence Rate at the Surgical Site as Measured by MRI</title>
        <description>The number of months for local recurrence via MRI</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-operative SRS</title>
            <description>All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
QOL via FACT-Br : Quality of Life via FACT-BR every 3 months for length of study.
Post-operative SRS : Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
MMSE : Neurocognitive function via MMSE done every 3 months for length of study.
MRI : MRI done every 3 months for the length of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Rate at the Surgical Site as Measured by MRI</title>
          <description>The number of months for local recurrence via MRI</description>
          <units>Months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Salvage Whole-brain Radiotherapy, Stereotactic Radiosurgery (SRS), or Surgery</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of New Brain Metastases Outside of the Adjuvant SRS Site</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the FACT-Br Subscales</title>
        <time_frame>Every 3 months for 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preservation of Neurocognitive Function as Measured by the Mini-Mental State Exam</title>
        <time_frame>Every 3 months for 12 months.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Significance (if Any) of Locally Recurrent Brain Metastasis at the Time of Their Occurrence (Mass Effect, Cognitive Functioning, and Other Symptoms)</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Death Due to Neurologic Causes</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Post-operative SRS</title>
          <description>All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
QOL via FACT-Br : Quality of Life via FACT-BR every 3 months for length of study.
Post-operative SRS : Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
MMSE : Neurocognitive function via MMSE done every 3 months for length of study.
MRI : MRI done every 3 months for the length of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Denise Lally-Goss, NP</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-3862</phone>
      <email>denise.lallygoss@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

